

- **Name:** Changhoon Yoo
 - **Current Position & Affiliation:** Asan Medical Center, University of Ulsan
College of Medicine
 - **Country:** Korea
-

- **Educational Background:**

M.D.

Received at 2006

Graduate Summa Cum Laude

University of Ulsan College of Medicine, Seoul, Korea

PhD.

Received at 2019

Postgraduate School, University of Ulsan College of Medicine, Seoul, Korea

Internship

Asan Medical Center, Seoul, Korea; MAR/2006-FEB/2007

Residency

Department of Internal Medicine, Asan Medical Center, Seoul, Korea;

MAR/2007-FEB/2011

Fellowship

Department of Oncology, Asan Medical Center, Seoul, Korea;

MAY/2014-FEB/2016

- **Professional Experience:**

Present Position:

Associate Professor, Department of Oncology, Asan Medical Center, University
of Ulsan College of Medicine, Seoul, Korea; MAR/2021 – Present

Previous Positions held:

Visiting Scholar, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los
Angeles, United States, JUL/2023 – DEC/2024

Assistant Professor, Department of Oncology, Asan Medical Center, University
of Ulsan College of Medicine, Seoul, Korea; MAR/2016 – FEB/2021

• Professional Organizations:

Member, Korean Medical Association
Member, Korean Association of Internal Medicine
Member, Korean Society of Medical Oncology
Member, Korean Cancer Association
Member, American Society of Clinical Oncology
Member, American Association for Cancer Research
Member, European Society of Medical Oncology
Member, Korean Liver Cancer Association
Member, International Liver Cancer Association

Faculty, Non-Colorectal section, European Society of Medical Oncology 2021 Annual Meeting; FEB/2020-OCT/2021
Faculty, International Liver Cancer Association, Educational Committee; FEB/2021 – Present
Head Faculty, GI section, Korean Society of Medical Oncology 2021 Annual Meeting; OCT/2020 – OCT/2021
Faculty, International Collaboration Division, Korean Society of Medical Oncology; MAR/2023 – Present
ESMO Leadership Programme Asia Alumni; NOV/2023 – DEC/2024
Faculty, GI cancer section, ESMO Asia 2025 ; JAN/2025 – Present

• Main Scientific Publications:

1. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. **Nat Med.** 2024 Mar;30(3):699-707. doi: 10.1038/s41591-024-02824-y. Epub 2024 Feb 19. PMID: 38374347; PMCID: PMC10957471. ***Co-corresponding author**
2. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. **Lancet Oncol.** 2021;22(11):1560-1572. ***First and corresponding author**
3. Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma. **J Hepatol.** 2024 Nov 10:S0168-8278(24)02666-7. doi: 10.1016/j.jhep.2024.10.043. Epub ahead of print. PMID: 39532185. ***Corresponding author**
4. Phase 2 trial of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. **Hepatology** 2023; 78(3), 758-770 ***First author**
5. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the stamp randomized trial. **Hepatology** 2023; 77(5), 1540-1549 ***Corresponding author**